Bio-Techne Corp

NASDAQ: TECH
$70.89
+$2.17 (+3.2%)
Closing Price on November 21, 2024

TECH Stock Chart and Intraday Price

TECH Stock Data

Asset Type Stock
Exchange NASDAQ
Currency USD
Country USA
Sector LIFE SCIENCES
Industry BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Address 614 MCKINLEY PL N E, MINNEAPOLIS, MN, US
Fiscal Year End June
Latest Quarter 12/31/2023
Market Cap 11,691.94M USD
Shares Outstanding 157,192,000
Bio-Techne Corp is a leading developer and manufacturer of life science reagents, instruments, and services. With a focus on research and clinical diagnostics, it offers a wide range of products including cytokines, growth factors, antibodies, and diagnostic assays. The company caters to the global market, providing tools for protein analysis, genetic screening, and oncology diagnostics. Bio-Techne, known for its innovation in cell and gene therapy, plays a crucial role in advancing scientific research and healthcare diagnostics.

TECH Articles

Watch the video below for a discussion about Microsoft’s (NASDAQ: MSFT) strategic shift under CEO Satya Nadella, focusing on future technologies like AI compared to previous leadership. The...
Thursday's premarket session was slightly positive, and it would take something major to push the markets in one direction or the other.
Tuesday's top analyst upgrades and downgrades included Accenture, Analog Devices, Apple, Baxter International, Best Buy, Coterra Energy, Emerson Electric, Johnson Controls, Lam Research, Micron...
Wednesday's top analyst upgrades and downgrades included Delta Air Lines, Hasbro, Illumina, Lululemon Athletica, Micron Technologies, Nike, Penn National, Shopify, Southwest Airlines, Starbucks and...
Wednesday's top analyst upgrades and downgrades included AMC Entertainment, Apple, Cerence, Chipotle Mexican Grill, Ciena, Dollar Tree, Freshpet, LATAM Airlines, Nio, Peloton Interactive, Ping, Tesla...
For health care investors, 2020 looks like a potentially good year after an especially fruitful JPMorgan Healthcare Conference this past week.
The top analyst upgrades, downgrades and initiations on Tuesday included Cars.com, Comerica, Cummins, Enbridge, Lyft, Micron Technology, Roku, Stryker, Uber Technologies, Visa and Western Digital.
The top analyst upgrades, downgrades and initiations seen on Monday included Alector, Bed Bath & Beyond, Dillard's, Foot Locker, Hasbro, Kraft Heinz, Vale, Xilinx and Zoetis.
The top analyst upgrades, downgrades and initiations seen on Tuesday included Boston Scientific, Etsy, General Electric, Morgan Stanley, SeaWorld, Skechers, Shopify, Square and Tesla.
According to a recent analyst report by Janney, the National Institute of Health budget that was approved last Friday could be a big boost for some select biopharma stocks.
Over the past five, 10 and 20 years, the life science and bioproduction segments have tended to outperform the S&P 500 more often than not.
The top analyst upgrades, downgrades and initiations seen on Thursday include Baker Hughes, Cree, Freeport-McMoRan, GrubHub, Silver Wheaton, Dynegy, Panera Bread and Ulta Beauty.
Jon OggInvestors frequently see analyst upgrades and Buy ratings from Wall Street research calls, but they often do not get to see the so-called Sell ratings. 24/7 Wall St. reviews many fresh...
Today almost feels like the "March of Biotech-inguins" because most of the movers were small companies you might otherwise miss.  Here were the big movers: Barrier Therapeutics (NASDAQ: BTRX) ran...